We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
-2.94%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
AUM
$1.5B
AUM Growth
-$339M
Cap. Flow
-$282M
Cap. Flow %
-18.81%
Top 10 Hldgs %
41.55%
Holding
80
New
12
Increased
20
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51M
2
NTRA icon
Natera
NTRA
+$41.9M
3
BDX icon
Becton Dickinson
BDX
+$37.3M
4
CYTK icon
Cytokinetics
CYTK
+$37M
5
ABT icon
Abbott
ABT
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 91.96%
2 Consumer Discretionary 1.59%
3 Financials 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SGEN
76
DELISTED
Seagen Inc. Common Stock
SGEN
-33,890
Closed -$5.24M
DICE
77
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
-74,774
Closed -$1.89M
ARYE
78
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
-500,000
Closed -$4.85M
LGV
79
DELISTED
Longview Acquisition Corp. II
LGV
-2,135,900
Closed -$21M
OHPA
80
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
-199,751
Closed -$1.95M

Similar funds

HealthCor Management's Q1 2022 Portfolio in Review

As of Q1 2022, HealthCor Management held 80 positions worth $1.5B, down 18% from $1.84B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

HealthCor Management withdrew a net $282M in Q1 2022, closing 16 positions and reducing 21 holdings. Its most notable exit was Medtronic, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, HealthCor Management opened a new position in Becton Dickinson worth $37.6M.

  • HealthCor Management's largest Q1 2022 buy was Becton Dickinson: 144,997 shares worth $37.6M.
  • HealthCor Management added most to BioMarin Pharmaceuticals in Q1 2022, an estimated $51M increase.
  • HealthCor Management's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $85.6M.
  • HealthCor Management fully exited Medtronic in Q1 2022, selling an estimated $158M.
  • HealthCor Management's ten largest holdings make up 42% of its $1.5B portfolio in Q1 2022.
  • HealthCor Management opened 12 new positions and closed 16 in Q1 2022.
  • HealthCor Management's portfolio value fell 18% quarter-over-quarter to $1.5B.

Based on HealthCor Management's 13F filing for Q1 2022, filed 16 May 2022.